As a prognostic value of [18F]GE180 PET could be shown in recurrent glioma patients, a longitudinal analysis of individual patients would be of high interest to address changes of TSPO expression and their prognostic value: An ideal study should obtain serial [18F]GE180 PET imaging of a cohort of, e.g., IDH wild-type glioblastoma patients prior to initial resection, before and after radiochemotherapy, during and after adjuvant chemotherapy, and at the time of (suspected) recurrence. The gene discussed is TSPO; the disease is glioblastoma.